Physician profile
Ryan Short
NPI 1568028967
$809.65
in general payments reported to CMS, 2019-2025
14 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2024: $34.50 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458 · Education: $53.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.37 |
| Education | $53.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $381.37 | 2025 | Flowtriever, Revcore Thrombectomy Catheter, Clottriever Bold Catheter |
| Genentech USA, INC. | $113.99 | 2021 | |
| Lilly USA, LLC | $52.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $45.97 | 2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $43.79 | 2021-2024 | Airsupra |
| Amarin Pharma, INC. | $31.37 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $28.45 | 2025 | Rexulti |
| Bard Peripheral Vascular, INC. | $21.25 | 2025 | Pristine |
| Tactile Systems Technology INC | $19.34 | 2024 | Flexitouch Plus, Entre Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.51 | 2021 | |
| Novo Nordisk INC | $16.18 | 2021 | |
| Merck Sharp & Dohme LLC | $15.90 | 2021 | |
| Glaxosmithkline, LLC. | $11.37 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.